191 related articles for article (PubMed ID: 36657725)
1. NMN: The NAD precursor at the intersection between axon degeneration and anti-ageing therapies.
Loreto A; Antoniou C; Merlini E; Gilley J; Coleman MP
Neurosci Res; 2023 Dec; 197():18-24. PubMed ID: 36657725
[TBL] [Abstract][Full Text] [Related]
2. The NAD
Llobet Rosell A; Paglione M; Gilley J; Kocia M; Perillo G; Gasparrini M; Cialabrini L; Raffaelli N; Angeletti C; Orsomando G; Wu PH; Coleman MP; Loreto A; Neukomm LJ
Elife; 2022 Dec; 11():. PubMed ID: 36476387
[TBL] [Abstract][Full Text] [Related]
3. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration.
Di Stefano M; Nascimento-Ferreira I; Orsomando G; Mori V; Gilley J; Brown R; Janeckova L; Vargas ME; Worrell LA; Loreto A; Tickle J; Patrick J; Webster JR; Marangoni M; Carpi FM; Pucciarelli S; Rossi F; Meng W; Sagasti A; Ribchester RR; Magni G; Coleman MP; Conforti L
Cell Death Differ; 2015 May; 22(5):731-42. PubMed ID: 25323584
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.
Sasaki Y; Zhu J; Shi Y; Gu W; Kobe B; Ve T; DiAntonio A; Milbrandt J
Exp Neurol; 2021 Nov; 345():113842. PubMed ID: 34403688
[TBL] [Abstract][Full Text] [Related]
5. SARM1 is a metabolic sensor activated by an increased NMN/NAD
Figley MD; Gu W; Nanson JD; Shi Y; Sasaki Y; Cunnea K; Malde AK; Jia X; Luo Z; Saikot FK; Mosaiab T; Masic V; Holt S; Hartley-Tassell L; McGuinness HY; Manik MK; Bosanac T; Landsberg MJ; Kerry PS; Mobli M; Hughes RO; Milbrandt J; Kobe B; DiAntonio A; Ve T
Neuron; 2021 Apr; 109(7):1118-1136.e11. PubMed ID: 33657413
[TBL] [Abstract][Full Text] [Related]
6. NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo.
Di Stefano M; Loreto A; Orsomando G; Mori V; Zamporlini F; Hulse RP; Webster J; Donaldson LF; Gering M; Raffaelli N; Coleman MP; Gilley J; Conforti L
Curr Biol; 2017 Mar; 27(6):784-794. PubMed ID: 28262487
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.
Alexandris AS; Ryu J; Rajbhandari L; Harlan R; McKenney J; Wang Y; Aja S; Graham D; Venkatesan A; Koliatsos VE
Neurobiol Dis; 2022 Sep; 171():105808. PubMed ID: 35779777
[TBL] [Abstract][Full Text] [Related]
8. SARM1-Dependent Axon Degeneration: Nucleotide Signaling, Neurodegenerative Disorders, Toxicity, and Therapeutic Opportunities.
McGuinness HY; Gu W; Shi Y; Kobe B; Ve T
Neuroscientist; 2023 Mar; ():10738584231162508. PubMed ID: 37002660
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological bypass of NAD
Liu HW; Smith CB; Schmidt MS; Cambronne XA; Cohen MS; Migaud ME; Brenner C; Goodman RH
Proc Natl Acad Sci U S A; 2018 Oct; 115(42):10654-10659. PubMed ID: 30257945
[TBL] [Abstract][Full Text] [Related]
10. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD
Sasaki Y; Nakagawa T; Mao X; DiAntonio A; Milbrandt J
Elife; 2016 Oct; 5():. PubMed ID: 27735788
[TBL] [Abstract][Full Text] [Related]
11. The chemical biology of NAD
Icso JD; Thompson PR
Curr Opin Chem Biol; 2022 Aug; 69():102176. PubMed ID: 35780654
[TBL] [Abstract][Full Text] [Related]
12. Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca(2+) Influx but Only Modestly Influenced by Mitochondria.
Loreto A; Di Stefano M; Gering M; Conforti L
Cell Rep; 2015 Dec; 13(11):2539-2552. PubMed ID: 26686637
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of initiation and regulation of axonal degeneration with special reference to NMNATs and Sarm1.
Funakoshi M; Araki T
Neurosci Res; 2023 Dec; 197():3-8. PubMed ID: 34767875
[TBL] [Abstract][Full Text] [Related]
14. A phase transition reduces the threshold for nicotinamide mononucleotide-based activation of SARM1, an NAD(P) hydrolase, to physiologically relevant levels.
Icso JD; Thompson PR
J Biol Chem; 2023 Nov; 299(11):105284. PubMed ID: 37742918
[TBL] [Abstract][Full Text] [Related]
15. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.
Loreto A; Hill CS; Hewitt VL; Orsomando G; Angeletti C; Gilley J; Lucci C; Sanchez-Martinez A; Whitworth AJ; Conforti L; Dajas-Bailador F; Coleman MP
Neurobiol Dis; 2020 Feb; 134():104678. PubMed ID: 31740269
[TBL] [Abstract][Full Text] [Related]
17. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons.
Gilley J; Orsomando G; Nascimento-Ferreira I; Coleman MP
Cell Rep; 2015 Mar; 10(12):1974-81. PubMed ID: 25818290
[TBL] [Abstract][Full Text] [Related]
18. Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection.
Shen H; Hyrc KL; Goldberg MP
Neurobiol Dis; 2013 Nov; 59():69-79. PubMed ID: 23892229
[TBL] [Abstract][Full Text] [Related]
19. Natural variants of human SARM1 cause both intrinsic and dominant loss-of-function influencing axon survival.
Ademi M; Yang X; Coleman MP; Gilley J
Sci Rep; 2022 Aug; 12(1):13846. PubMed ID: 35974060
[TBL] [Abstract][Full Text] [Related]
20. The SARM1 axon degeneration pathway: control of the NAD
Figley MD; DiAntonio A
Curr Opin Neurobiol; 2020 Aug; 63():59-66. PubMed ID: 32311648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
